Andrew Simon Bell

USPTO Granted Patents = 29 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 218(Granted Patents)

Location History:

Sandwich, GB (1997 - 2014)
Kent, GB (2020)
United Kingdom, GB (2022)
Dundee, GB (2023)
Deal, GB (1994 - 2024)

Company Filing History:

Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

patents

5. 2 out of 9

Viiv Healthcare UK Limited

patents

6. 1 out of 523

Pharmacia & Upjohn Company

Evotec International Gmbh

patents

where one patent can have more than one assignee

Years Active: 1994-2024

Loading Chart...

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12180213 - Substituted pyrazoles showing serotonin 5-HT receptor activity (2024-12-31),

2. 12060355 - Compounds for use in the treatment of fascioliasis (2024-08-13),

3. 11786528 - Pyrazolopyrimidine compounds as adenosine receptor antagonists (2023-10-17),

4. 11466007 - Substituted lactams showing serotonin 5-HT receptor activity (2022-10-11),

5. 11339151 - Aliphatic acid amide derivative (2022-05-24),

6. 11046700 - Substituted imidazo[1,2-a]pyrazines, pyrazolo[1,5-c]pyrimidines, pyrazolo[1,5-a]pyridines, and purines for the treatment of schistosomiasis (2021-06-29),

7. 10745401 - Condensed lactam derivative (2020-08-18),

8. 10577363 - Substituted piperidine compounds (2020-03-03),

9. 9447116 - Inhibitors of HIV replication (2016-09-20),

10. 8809363 - Inhibitors of HIV replication (2014-08-19),

11. 8772343 - Chemical compounds (2014-07-08),

12. 8685977 - Chemical compounds (2014-04-01),

13. 8592629 - Sulfonamide derivatives as Nav 1.7 inhibitors (2013-11-26),

14. 8097621 - Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors (2012-01-17),

15. 7943628 - Pyrimidine derivatives (2011-05-17),

Title: Andrew Simon Bell: Innovator in Neuropsychiatric and Parasitic Disease Treatments

Introduction

Andrew Simon Bell, located in Sandwich, GB, is a prolific inventor with an impressive portfolio of 27 patents to his name. His innovative contributions primarily focus on medical treatments, particularly in the realms of neuropsychiatric diseases and parasitic infections.

Latest Patents

Among his latest patents, Bell has made significant advancements including a medicament for treating neuropsychiatric diseases that comprises a compound showing serotonin 5-HT receptor activity. This innovative medicament presents a new approach to addressing various neuropsychiatric conditions. Additionally, he has developed compounds aimed at the treatment of fascioliasis, which are novel in their composition and functionality as growth inhibitors. These compounds have the potential to revolutionize treatments not only for fascioliasis but also for schistosomiasis, contributing significantly to pharmaceutical medicine.

Career Highlights

Throughout his career, Andrew has contributed his expertise to major pharmaceutical companies, including Pfizer Corporation and Merck Patent GmbH. His work has placed him at the forefront of innovative medical solutions, showcasing a strong commitment to improving health outcomes through pharmaceutical advancements.

Collaborations

Bell has collaborated with notable peers in the industry, including David Graham Brown and Ian Roger Marsh. These partnerships have further fueled his innovative endeavors, allowing for the exchange of ideas and expertise that enhance the efficacy of his inventions.

Conclusion

Andrew Simon Bell stands as a notable figure in the landscape of medical innovation. With a wealth of patents to his credit, his contributions signify a dedication to addressing critical health issues through inventive solutions. His work continues to pave the way for advancements in treatment methodologies, positively impacting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.